Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11152MR)

This product GTTS-WQ11152MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454
UniProt ID P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11152MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4602MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ15671MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ5018MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ455MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ6417MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ3890MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ14630MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ6450MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW